Assembly Biosciences, Inc. (ASMB) has released promising interim results from its Phase 1a study of ABI-5366, a long-acting herpes simplex virus (HSV) inhibitor. The drug demonstrated a favorable safety profile and extended pharmacokinetic (PK) profile, potentially leading to once-weekly or even once-monthly oral dosing for recurrent genital herpes.